BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24025389)

  • 21. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
    Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
    Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
    Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
    J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients.
    De Vita F; Orditura M; Auriemma A; Infusino S; Catalano G
    J Exp Clin Cancer Res; 1998 Dec; 17(4):413-7. PubMed ID: 10089060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
    Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
    Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer.
    Lin Q; Chen T; Lin Q; Lin G; Lin J; Chen G; Guo L
    J Surg Oncol; 2013 Jun; 107(7):767-71. PubMed ID: 23609137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer.
    Marchevsky AM; Patel S; Wiley KJ; Stephenson MA; Gondo M; Brown RW; Yi ES; Benedict WF; Anton RC; Cagle PT
    Mod Pathol; 1998 Jul; 11(7):618-25. PubMed ID: 9688182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY; Choi BG; Choi JY; Lee SY; Ju SY
    Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression and diagnosis value of Fascin in non-small cell lung cancer patients].
    Liu YG; Gao XD; Yue WT
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2505-7. PubMed ID: 24300277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of serum proteome components associated with progression of non-small cell lung cancer.
    Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
    Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
    Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
    Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum HE4 as a diagnostic and prognostic marker for lung cancer.
    Iwahori K; Suzuki H; Kishi Y; Fujii Y; Uehara R; Okamoto N; Kobayashi M; Hirashima T; Kawase I; Naka T
    Tumour Biol; 2012 Aug; 33(4):1141-9. PubMed ID: 22373583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A.
    Kanoh Y; Abe T; Masuda N; Akahoshi T
    Oncol Rep; 2013 Feb; 29(2):469-73. PubMed ID: 23135313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.